A Phase 4 interventional study of Intraosseous access and Intravenous in Cardiac Arrest, sponsored by Lars Wiuff Andersen. Active, not recruiting at 5 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Lars Wiuff Andersen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Heart Arrest with a site in Denmark — 6 open to participants now, 11 under way, none of them phase 3. Heart Arrest · Denmark.
Among the 36 studies in Heart Arrest with a site in Denmark, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 4, reaches primary completion later than 0 of the 10 other live ones, and was the 30th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →6 of the 36 studies in Heart Arrest with a site in Denmark are open now. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 18+
Lars Wiuff Andersen · Sites in Denmark
Ages 18+
University of Aarhus · Sites in Denmark, Norway
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18–65
Emergency Medical Services, Capital Region, Denmark · Sites in Denmark
Ages 8+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 1 · Phase 4 5
First in 2007; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,479 is above the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 274 across the 26 interventional studies, 157 across the 10 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 36 has an industry lead sponsor. The 10 most frequent:
Lars Wiuff Andersen is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Lars Wiuff Andersen has 4 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Arrest with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04446585Emergency Medical Services, Capital Region, DenmarkCardiac Arrest in Residential Areas With Mobile First-responder Activation | 2027-01 |
| NCT06809309University of AarhusThe Ventilation During In-hospital Cardiac Arrest Study | 2027-04 |
| NCT05173740Rigshospitalet, DenmarkRehabilitation for Survivors of Out-of-hospital Cardiac Arrest | 2027-07-31 |
| NCT06979700University of AarhusEarly WAKE-up Predictors After Out-of-Hospital Cardiac Arrest | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Heart Arrest with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The "Intravenous vs. Intraosseous Vascular Access During Out-of-Hospital Cardiac Arrest (IVIO)"-trial is an investigator-initiated, randomized, parallel group, patient and outcome assessor-blinded, superiority trial of intravenous vs. intraosseous vascular access during adult out-of-hospital cardiac arrest. The intraosseous group will be further randomized to humeral vs. tibial access. The trial will be conducted in the Central Denmark Region. The primary outcome will be sustained return of spontaneous circulation, and 762 patients will be included. Key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention will consist of attempts to successfully establish a peripheral intravenous access during the cardiac arrest. The prehospital clinician will be required to attempt the intervention a minimum of two times.
Device: Intravenous
The intervention will consist of attempts to successfully establish an intraosseous access during the cardiac arrest. The prehospital clinician will be required to attempt the intervention a minimum of two times.
Device: Intraosseous access
Needle placed in the bone marrow.
Needle placed in a vein.
Sustained return of spontaneous circulation
Palpable pulses or other signs of circulation without a need for chest compressions lasting at least 20 minutes
Time frame: Before or after hospital arrival (up to 2 hours after the cardiac arrest)
Survival
Time frame: 30 days after the cardiac arrest
Favorable neurological outcome
Neurological outcome will be assessed with the modified Rankin Scale (mRS) which is a scale from 0 to 6 assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes. The scale will will be dichotomized as favorable (mRS 0-3) vs. unfavorable (mRS 4-6).
Time frame: 30 days after the cardiac arrest
Plan to share: Yes — Six months after the publication of the last results, all de-identified individual patient data will be made available for data sharing.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Ran from Mar 2022 to primary completion in May 2024, 26 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lars Wiuff Andersen